Infect Chemother.  2016 Sep;48(3):174-180. 10.3947/ic.2016.48.3.174.

Clinical and Economic Evaluation of Multidrug-Resistant Acinetobacter baumannii Colonization in the Intensive Care Unit

• Lee H
• Lee H

• KMID: 2466429
• DOI: http://doi.org/10.3947/ic.2016.48.3.174

Abstract

BACKGROUND
The clinical and economic impact of multidrug-resistant (MDR) Acinetobacter baumannii colonization remains unclear. This study aimed to estimate and compare the mortality rates, length of stay (LOS), and hospitalization costs in the intensive care unit (ICU) for MDR A. baumannii colonized patients and a matched population.
MATERIALS AND METHODS
We performed a retrospective propensity score matched cohort study comparing the outcomes of patients with MDR A. baumannii colonization with those of uncolonized subjects matched at the time they were admitted to the ICU between January 2012 and December 2014.
RESULTS
During the study period, 375 (7.5%) of the 4,779 patients were colonized with MDR A. baumannii. One hundred and twenty-two MDR A. baumannii colonized patients were compared with 122 uncolonized patients using propensity score matching. MDR A. baumannii colonized patients were likely to have a higher mortality rate compared to uncolonized patients (49.2% vs 32.0%; odds ratio [OR], 3.64). A longer ICU LOS and total admission days were observed in the MDR A. baumannii colonized patient group (4.14 and 4.67 days increase, OR 1.41 and 1.19). MDR A. baumannii colonization patients had an average extra ICU and total admission cost of $1,179 (â‚©1,261,334) and $1,333 (â‚©1,422,032) according to a multivariable regression model (OR, 1.27 and 1.17). Multivariable analysis identified the factors affecting ICU cost, which included, MDR A. baumannii colonization (OR = 1.33; P = 0.001), ICU LOS (OR = 1.97; P <0.001), valvular heart disease (OR = 1.12; P = 0.005), invasive devices (OR = 1.15; P = 0.018), and surgery (OR = 1.1; P <0.001).
CONCLUSION
MDR A. baumannii colonization was associated with increased mortality, LOS, and costs in the ICU. A strict infection control program including preemptive isolation for high-risk groups would be helpful for reducing the burden of this infection.

Keyword

Acinetobacter baumannii; Infection control; Intensive care units

MeSH Terms

Acinetobacter baumannii*
Acinetobacter*
Cohort Studies
Colon*
Cost-Benefit Analysis*
Critical Care*
Heart Valve Diseases
Hospitalization
Humans
Infection Control
Intensive Care Units*
Length of Stay
Mortality
Odds Ratio
Propensity Score
Retrospective Studies

Reference

1. Holmberg SD, Solomon SL, Blake PA. Health and economic impacts of antimicrobial resistance. Rev Infect Dis. 1987; 9:1065–1078.

2. Howard A, O’Donoghue M, Feeney A, Sleator RD. Acinetobacter baumannii: an emerging opportunistic pathogen. Virulence. 2012; 3:243–250.

3. Peleg AY, Seifert H, Paterson DL. Acinetobacter baumannii: emergence of a successful pathogen. Clin Microbiol Rev. 2008; 21:538–582.

4. Montefour K, Frieden J, Hurst S, Helmich C, Headley D, Martin M, Boyle DA. Acinetobacter baumannii: an emerging multidrug-resistant pathogen in critical care. Crit Care Nurse. 2008; 28:15–25.

5. Young LS, Sabel AL, Price CS. Epidemiologic, clinical, and economic evaluation of an outbreak of clonal multidrug-resistant Acinetobacter baumannii infection in a surgical intensive care unit. Infect Control Hosp Epidemiol. 2007; 28:1247–1254.

6. Kwak YG, Cho YK, Kim JY, Lee MS, Kim HY, Kim YK, Park ES, Jin HY, Kim HB, Kim ES, Jeong SY, Eom JS, Kim SR, Lee JY, Hong HK, Sung JH, Uh Y, Lee YS, Oh HB, Kim EC; Korean Nosocomial Infections Surveillance System (KONIS). Korean nosocomial infections surveillance system, intensive care unit module report: data summary from July 2009 through June 2010. Korean J Nosocomial Infect Control. 2011; 16:1–12.

7. Cheon S, Kim MJ, Yun SJ, Moon JY, Kim YS. Controlling endemic multidrug-resistant Acinetobacter baumannii in Intensive Care Units using antimicrobial stewardship and infection control. Korean J Intern Med. 2016; 31:367–374.

8. Jung E, Byun S, Lee H, Moon SY, Lee H. Vancomycin-resistant Enterococcus colonization in the intensive care unit: clinical outcomes and attributable costs of hospitalization. Am J Infect Control. 2014; 42:1062–1066.

9. Paterson DL. The epidemiological profile of infections with multidrug-resistant Pseudomonas aeruginosa and Acinetobacter species. Clin Infect Dis. 2006; 43:Suppl 2. S43–8.

10. von Graevenitz A. Acinetobacter, Alcaligenes, Moraxella, and other nonfermentative gram-negative bacteria. In : Murray PR, Baron EJ, Pfaller MA, Tenover FC, Yolken RH, editors. Manual of clinical microbiology. 6th ed. Washington, DC: American Society for Microbiology;1995. p. 520–532.

11. Clinical and Laboratory Standards Institute (CLSI). Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically. Wayne, PA: CLSI;2006. p. M7–A7.

12. Garnacho-Montero J, Ortiz-Leyba C, Fernández-Hinojosa E, Aldabó-Pallás T, Cayuela A, Marquez-Vácaro JA, Garcia-Curiel A, Jiménez-Jiménez FJ. Acinetobacter baumannii ventilator-associated pneumonia: epidemiological and clinical findings. Intensive Care Med. 2005; 31:649–655.

13. Luna CM, Aruj PK. Nosocomial Acinetobacter pneumonia. Respirology. 2007; 12:787–791.

14. Park YJ, Jeong JS, Park ES, Shin ES, Kim SH, Lee YS. Survey on the infection control of multidrug-resistant microorganismsin general hospitals in Korea. Korean J Nosocomial Infect Control. 2007; 12:112–121.

15. Blot S, Vandewoude K, De Bacquer D, Colardyn F. Nosocomial bacteremia caused by antibiotic-resistant gram-negative bacteria in critically ill patients: clinical outcome and length of hospitalization. Clin Infect Dis. 2002; 34:1600–1606.

16. Boyce JM. Environmental contamination makes an important contribution to hospital infection. J Hosp Infect. 2007; 65:Suppl 2. 50–54.

17. Dancer SJ. The role of environmental cleaning in the control of hospital-acquired infection. J Hosp Infect. 2009; 73:378–385.

18. Weingarten CM, Rybak MJ, Jahns BE, Stevenson JG, Brown WJ, Levine DP. Evaluation of Acinetobacter baumannii infection and colonization, and antimicrobial treatment patterns in an urban teaching hospital. Pharmacotherapy. 1999; 19:1080–1085.

19. García-Garmendia JL, Ortiz-Leyba C, Garnacho-Montero J, Jiménez-Jiménez FJ, Monterrubio-Villar J, Gili-Miner M. Mortality and the increase in length of stay attributable to the acquisition of Acinetobacter in critically ill patients. Crit Care Med. 1999; 27:1794–1799.

20. Rodríguez-Baño J, García L, Ramírez E, Martínez-Martínez L, Muniain MA, Fernández-Cuenca F, Beltrán M, Gálvez J, Rodríguez JM, Velasco C, Morillo C, Perez F, Endimiani A, Bonomo RA, Pascual A. Long-term control of hospital-wide, endemic multidrug-resistant Acinetobacter baumannii through a comprehensive "bundle" approach. Am J Infect Control. 2009; 37:715–722.

21. Muto CA, Jernigan JA, Ostrowsky BE, Richet HM, Jarvis WR, Boyce JM, Farr BM. SHEA.SHEA guideline for preventing nosocomial transmission of multidrug-resistant strains of Staphylococcus aureus and enterococcus. Infect Control Hosp Epidemiol. 2003; 24:362–386.

22. Huskins WC, Huckabee CM, O’Grady NP, Murray P, Kopetskie H, Zimmer L, Walker ME, Sinkowitz-Cochran RL, Jernigan JA, Samore M, Wallace D, Goldmann DA. STAR*ICU Trial Investigators. Intervention to reduce transmission of resistant bacteria in intensive care. N Engl J Med. 2011; 364:1407–1418.

23. Weber SG, Huang SS, Oriola S, Huskins WC, Noskin GA, Harriman K, Olmsted RN, Bonten M, Lundstrom T, Climo MW, Roghmann MC, Murphy CL, Karchmer TB; Society for Healthcare Epidemiology of America. Association of Professionals in Infection Control and Epidemiology. Legislative mandates for use of active surveillance cultures to screen for methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococci: position statement from the Joint SHEA and APIC Task Force. Infect Control Hosp Epidemiol. 2007; 28:249–260.